Management of Disseminated Cutaneous Herpes Simplex Virus Infection

Clinical Recognition and Risk Assessment

Extensive cutaneous lesions that involve areas beyond a single dermatome or localized region are a hallmark of disseminated HSV infection. CDC recommends recognizing this pattern as a trigger for urgent therapy. 1
Systemic manifestations such as fever and signs of visceral involvement (e.g., encephalitis, pneumonitis, hepatitis) frequently accompany widespread skin disease and indicate severe infection. CDC. 8

Immunocompromised individuals—including patients with HIV/AIDS, malignancy, or receiving immunosuppressive agents—are at markedly increased risk for disseminated HSV and should receive immediate aggressive antiviral therapy. CDC. 5
Neonates with disseminated disease constitute a distinct high‑risk group requiring neonatal‑specific dosing regimens. CDC. 10

Immediate hospitalization and administration of intravenous acyclovir at 5–10 mg/kg every 8 hours is the first‑line treatment for disseminated cutaneous HSV in adults and children (non‑neonatal). Therapy should continue for a minimum of 5–7 days or until clinical resolution. CDC. 1
For neonates with CNS involvement, the recommended dose is 20 mg/kg IV three times daily for 21 days; for disease limited to skin, eye, and mouth, a 14‑day course is advised. CDC. 10

In immunocompetent patients, intravenous therapy may be stopped after 5–7 days once lesions begin to regress; immunocompromised patients often require prolonged courses because of extended disease duration. CDC. 2
After clinical improvement, transition to oral acyclovir is recommended, typically 400 mg taken five times daily in adults (dose adjusted for weight and age). CDC. 10

Lack of clinical improvement after 7–10 days of appropriate IV acyclovir should prompt evaluation for acyclovir‑resistant HSV; the preferred alternative is foscarnet 40 mg/kg IV three times daily (or 60 mg/kg IV twice daily). CDC. 10
Additional agents with limited case‑report evidence for resistant HSV include cidofovir (topical or systemic), brincidofovir, and imiquimod. Infectious Diseases Society of America (IDSA). 11
Acyclovir‑resistant strains are most common in patients with prolonged antiviral exposure, especially those with HIV infection or who are transplant recipients. CDC. 7

Neonates with disseminated HSV require the higher-dose acyclovir regimen (20 mg/kg IV TID) and longer treatment duration as outlined above. CDC. 10

Persons living with HIV may need more aggressive and extended antiviral courses; suppressive oral acyclovir therapy is often recommended according to HIV opportunistic infection guidelines. CDC. 9

These patients experience prolonged, extensive disease and carry the highest risk for acyclovir resistance, frequently necessitating alternative antivirals such as foscarnet or cidofovir. CDC. 5

Topical acyclovir alone is insufficient for disseminated disease and should be avoided; systemic therapy is mandatory. CDC. 3
Initiation of antiviral therapy should not be delayed while awaiting laboratory confirmation when clinical suspicion is high, to prevent rapid progression to life‑threatening complications. CDC. 8
Clinicians must monitor for visceral dissemination (encephalitis, pneumonitis, hepatitis) and be prepared to extend therapy beyond the standard 7‑day course when such complications occur. CDC. 4